Opdualag nivolumab and relatlimab

Drug Class

LAG-3 and PD-1 monoclonal antibody combination

Mechanism

Fixed-dose combination of relatlimab (LAG-3 blocker) and nivolumab (PD-1 blocker), cooperatively releasing T-cell inhibition to enhance antitumor immune responses.

Approved Indication

Unresectable or metastatic melanoma in adult and pediatric patients aged 12 years or older, per its FDA approval.

What This Means For Patients

Opdualag is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources

Pivotal Clinical Evidence

• RELATIVITY-047 — Tawbi et al., N Engl J Med 2022 (NCT03470922) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf